Syncromune

Syncromune is an oncology-focused biopharmaceutical company committed to developing therapies that may improve the lives of cancer patients. Our focus centers around conducting clinical research that evaluates the safety and effectiveness of new therapies for patients with solid tumor cancers. Our clinical trial programs are the primary way to get access to a Syncromune investigational therapy. These clinical trials provide the most effective way to assess how our investigational therapies may treat cancer, and are used to support regulatory approval.

At this time, Syncromune does not provide access to investigational therapies outside of clinical trials or prior to regulatory approval. You and your health care provider may learn more about our clinical trials by going to the clinical trials section of our website, or visiting ClinicalTrials.gov and searching for Syncromune.

If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to trials@syncromune.com. Syncromune will acknowledge your request as soon as possible, typically within 3 days of receipt.

If applicable, this website will be updated with hyperlinks to the relevant expanded access information on ClinicalTrials.gov. Syncromune reserves the right to revise this expanded access policy at any time.

Pursuant to the 21st Century Cures Act, the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual.